There was nothing precision about selecting patient for current phase2b trial, that will be for next phase 3 trial which is coming in another 5 year. Precision medicine is another hot air Misleading spew in every conf call. Misleading will be doing subgroup analysis to see the signal and then design next phase 3 AD trial that is where he will have patience selected based on certain genome data.